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Short tile: Genotyping and phenotyping of familial acromegaly
Keywords: acromegaly, gigantism, IGF-I, GH, pituitary adenoma, AIP gene variant, familial 
acromegaly 
Phenotypic and genotypic features of a large kindred with a 
germline AIP variant
Abstract
Context: Acromegaly is usually a sporadic disease, but familial cases occur. Mutations in the 
aryl hydrocarbon receptor-interacting protein (AIP) gene are associated with familial 
pituitary adenoma predisposition. However, the pathogenicity of some AIP variants remains 
unclear and additional unknown genes may be involved.
Objective: To explore the phenotype and genotype of a large kindred carrying the p.R304Q 
AIP variant. 
Methods: The family comprised 52 family members at risk of carrying the p.R304Q AIP 
variant including a case with gigantism and one with acromegaly and several family 
members with acromegalic features. Nine family members (three trios) underwent exome 
sequencing to identify putative pathogenic variants. 
Results: We identified 31 p.R304Q carriers and based on two cases with somatotropinomas 
the disease penetrance was 6%. We observed physical signs of acromegaly in several family 
members, which were independent of AIP status. Serum Insulin-like Growth Factor-I (IGF-I) 
levels in all family members were above the mean for age and sex [IGF-I SDS: +0.6 (CI95% 
+0.4-0.9), p<0.01]. Exome analysis identified two candidate genes: PDE11A, known to be 
associated with the development of adrenal tumors, and ALG14 that co-segregated with the 
variant AIP gene. Ten asymptomatic p.R304Q family members (age>50 years) were screened 
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Conclusions:  This large family adds new information on the p.R304Q AIP variant and data 
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Introduction
Pituitary adenomas are some of the most frequent intracranial tumors with a prevalence of 
up to 800 per million people of which a small proportion is familial (hereditary) 1. Mutations 
in the aryl hydrocarbon receptor-interacting protein gene (AIP) predispose to the 
development of pituitary adenomas 2 and account for ≈ 20% of the familial isolated pituitary 
adenoma patients and 4% of unselected sporadic pituitary adenoma cases, respectively 1,3. 
The inheritance pattern is autosomal dominant with an age-dependent penetrance of 20-23 
% 3. The low disease penetrance could theoretically be due to additional disease-modifying 
genes 4. FGFR4 has been suggested to influence acromegaly development, but it was not 
found to alter penetrance in AIP mutation positive families 5. Members of the 
phosphodiesterase family regulate the cAMP pathway, which is known to play a key role in 
somatotroph tumorigenesis. PDE11A can modify adrenal adenoma risk 6,7 and their role in 
pituitary tumorigenesis has being studied 8,9. The AIP gene is suggested to be a tumor 
suppressor gene and more than 100 different ‘pathogenic’ or ‘likely pathogenic’ germline AIP 
variants have been described 1,5 and additional variants are currently considered to be of 
unknown significance 3. Patients with AIP mutations are predominantly young patients with 
large tumors that respond poorly to conventional treatment 1. Identification of AIP mutation 
positive patients prompts the detection of carriers with otherwise unrecognized disease, 
potentially leading to earlier diagnosis and improved prognosis 5,10,11. 
In the present study, we describe the genotype and phenotype of a large kindred with the 
p.R304Q AIP variant, including two index cases with gigantism and acromegaly, respectively. 
Subjects and methods
Family tree, genetic screening and exome analysis
We examined the entire family tree of the two index patients (cases 1 and 2, described 
below) for five generations (fig. 1). Both index patients carried a p.R304Q AIP variant 
without detectable mutations in the MEN1 gene.  All family members at risk of carrying the 
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prolactin. Carriers of the p.R304Q AIP variant were subsequently examined by a pituitary 
MRI in addition to annual measurements of GH, IGF-I and prolactin. Children in the family 
were followed by paediatricians from the age of 5 years with annual GH, IGF-I and prolactin 
measurements, growth charts, and a pituitary MRI after the age of 12 years. 
Three trios, each consisting of two parents and one child (fig. 2) from the family, 
were selected for exome sequencing to identify putative mutations (‘gene-x’) that could be 
involved in the formation of pituitary adenomas.  The first trio included index case 1 with 
gigantism carrying the p.R304Q variant and his parents with an asymptomatic father 
carrying the p.R304Q variant and the mother without the p.R304Q variant (fig. 2A). The 
second trio included index case 2 with acromegaly and her healthy husband and their son 
(case 3, described later), who exhibited acromegalic features without carrying the p.R304Q 
variant (fig. 2B). The third trio included a male carrier of the p.R304Q variant, who 
presented acromegalic features without biochemical or radiological evidence of acromegaly  
(case 4, described later) and his two parents where the mother was an asymptomatic 
carrier of the p.R304Q variant (fig. 2C). 
Serum GH and IGF-I levels and height measurements
Analysis of GH and IGF-I was centralised and measured, as previously described 12. IGF-I 
standard deviation scores (IGF-SDS) were calculated using age- and sex-specific reference 
values for each IGF-I measurement 13.
Target height estimates were calculated based on data from the Department of 
Growth and Reproduction at the Danish National Hospital. Target height was calculated 
using the mid-parental height +6.5 cm/-6.5 cm for males/females respectively, with a 
confidence interval of ±8.5 cm 14. Standard deviations scores (SDS) for height were 
calculated based on a Danish reference cohort 15. 
Exome analysis
Genomic DNA libraries were derived from blood samples. Libraries were made with Kapa 
Hyper Library Prep Kit (KapaBiosystems, Wilmington, MA, USA) followed by exome capture 
using Nimblegen SeqCap EZ Exome v3.0 Capture Kit (Roche). Indexed libraries were paired-
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million read pairs were sequenced per sample yielding a median exome coverage of 141 
(range 83-268). Exome analysis: Fastq files were demultiplexed using bcl2fastq (v2.15) and 
were quality checked using fastQC and fastqScreen 16.  Adapter sequences were trimmed 
using TrimGalore (v0.4.1) and Cutadapt (v1.9). The paired end sequences were mapped 
using bwa mem (0.7.5a-r405) to the hg19 reference genome. PCR and optical duplicates 
were removed from each library independently (Picard package (v2.0.1, 17 )and the final 
bam file was realigned (GATK v3.6 IndelRealigner 18) and its base quality scores were 
adjusted in regions with technical artifacts (GATK BaseRecalibrator) using data from dbSNP, 
1000G, Mills and 1000G gold standard indels. Basic alignment statistics were calculated 
using different Picard tools. SNPs and short indels were called using GATK HaplotypeCaller 
18. Individual samples were called in combination with a large combined database of other 
in-house sequenced samples (1658 gVCF files). This strategy increases the sensitivity at low 
coverage regions and powers the statistical filtering model that will evaluate the validity of 
the individual calls. Genomic variants were analyzed using Ingenuity Variant Analysis 
version 3.1.20150407 19. 
Statistics
Histogram and qq-plot were used to examine continuous variables for normal distribution. 
Normally distributed data were expressed as mean±95% confidence interval (CI) and non-
normal distribution data as median±IQR (interquartal range). If data were not normally 
distributed, log transformation was applied to archive normal distribution for further 
statistical use. Student’s paired or unpaired t-tests were used to compare variables within or 
between groups, respectively. The study was approved by the Danish Ethical Committee (1-
10-72-117-14) and by the Danish Data Protection Agency (1-16-02-358-14). Consent has 
been obtained from each patient or subject involved in exome analyses after full explanation 
of the purpose and nature of all procedures used, including the use of pictures (case 3). The 
data that support the findings of this study are available from the corresponding author 
upon reasonable request.
Results
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Case 1: 37-year-old male presented in 2010 with joint pain, muscle weakness, and signs of 
gigantism including frontal bossing, prognathism, and enlarged hands and feet. The patient’s 
height was 207 cm (+4 SDS-height) with a target height of 185±8.5 cm. The mean serum GH 
level during a day curve was 1.3 ug/l and the nadir GH during a glucose suppression test was 
0.9 ug/l (< 0.4 ug/l). The serum IGF-I was 340 ug/l (3.3 IGF-SDS) and the prolactin level was 
normal. A contrast enhanced pituitary MRI (1.5 tesla) gave the suspicion of a small pituitary 
lesion but without a distinct pituitary adenoma (fig. 3 ). A whole body PET-CT using a 
DOTATOC tracer did not disclose pathologic uptake outside the sellar region.  His medical 
history suggested the occurrence of a pituitary apoplexy approximately 10 years prior to the 
gigantism diagnosis with a self-limited episode of severe headache, nausea, and visual 
symptoms.  The patient was treated with Lanreotide Autogel at a final dose of 120 mg/4 
weeks resulting in normalization of serum IGF-I (183 ug/l, 0.0 IGF-SDS), fasting GH of 0.7 
ug/L and a GH nadir of 0.57 ug/l.  A subsequent MRI performed in 2012 indicated growth of 
the pituitary lesion and the presence of a pituitary microadenoma (fig. 3). Genetic testing 
revealed a variant of unknown significance in the AIP gene: c.911G>A, p.R304Q.
Case 2: A paternal aunt of the index patient was diagnosed with acromegaly in 
1988 at the age of 37 years. At that point, she presented elevated fasting GH levels (30 ug/l), 
borderline elevated prolactin (22 ug/l (< 18 ug/l)), and a pituitary adenoma with a maximal 
diameter of 10 mm. Her height was 180 cm, whereas her target height was 165 cm 
corresponding to 1.7 SDS-height. In consistency with a presumed early disease onset, 
physical signs of acromegaly were noticeable on family-photos before the age of 22.  One 
month prior to transsphenoidal surgery, the patient experienced an episode of severe 
headache, nausea and vomiting, which lasted for three days. At surgery signs of a recent 
pituitary apoplexy within a cystic pituitary adenoma was noted. Postoperatively, due to 
hypopituitarism, the patient was replaced with hydrocortisone, levothyroxine and GH. 
Case 3: A 29-year-old healthy son of index case 2 exhibited acromegalic 
features with frontal bossing, a large jaw and large hands, but did not carry the p.R304Q 
variant and had normal IGF-I values 183 ug/l (0.72 IGF-SDS).  The patient had remarkable 
physical similarities to his cousin with gigantism (case 1). His actual height was 188 cm, and 
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on his grandparents’ heights) as his mother’s (case 2) height could not be used as she had 
early onset acromegaly.
Case 4: A 44-year-old male carrier of the p.R304Q variant who exhibited an 
acromegalic appearance with frontal bossing, prognathism, and enlarged hands and feet 
(shoe size 49, fig. 4). His height was 193 cm as compared to a target height of 187 cm± 6.5cm 
corresponding to 1.8 SDS-height, but without additional acromegalic features. He used no 
prescription medicine, but was diagnosed with migraine during adolescence. The episodes of 
migraine culminated when he reached the age of 35 years where he experienced periods 
with severe headaches, nausea and transient loss of sight. During the subsequent years, the 
migraine episodes became less severe and frequent. He displayed slightly elevated IGF-I 
levels estimated by two different assays: iSYS: 239 ug/l (2.37 IGF-SDS) and Liaison: 35.6 
nmol/l (11.5-27.3 nmol/L), but a normal GH suppression during glucose tolerance testing 
with a nadir GH level of 0.1 ug/l. Two normal pituitary MRIs were performed at two-years 
interval. 
p.R304Q AIP variant screening
A total of 159 individuals were identified covering five generations from a common ancestor 
couple who had 14 children. In the second generation, all individuals were deceased except 
for an 80-year-old male who carried the p.R304Q variant without evidence of acromegaly. 
None of his 13 siblings were diagnosed with acromegaly. 
Genetic screening of 72 surviving family members identified six of the 14 
siblings as carriers of the AIP p.R304Q variant putting at risk 52 family members of 
inheriting the mutation, including the two index cases (fig. 1). The sex distribution among 
the individuals at risk was equal (25 males/27 females). Among the 50 healthy predisposed 
family members, including both variant carriers (304Q+, n=29) and variant non-carrier 
(304Q-, n=21) individuals, IGF-I-SDS levels were significantly elevated  (0.6 SDS (CI95% 0.4-
0.9), p<0.01, fig. 5) and several members exhibited acromegalic traits independent of AIP 
variant status (304Q +: IGF-I 0.6 SDS (CI95% 0.2-0.9); 304Q -: IGF-I 0.7 SDS (CI95% 0.4-1.1), 
p=0.5). Among the 304Q + members, the average age was 39 years (CI95% 31.0-46.1). Based 
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the case with NFPA, the prevalence was 10% and 13% among patients older than 30 years11. 
Additional hormone measurements showed normal serum levels of prolactin and a mean 
random GH concentration of 0.7 ug/l (CI95% 0.1-1.3). 
One p.R304Q variant carrier (case 5) without symptoms or signs of hormonal 
hypersecretion presented with an intrasellar cystic lesion on the initial MRI and an 
intrasellar microadenoma (7 x 4 mm) on a second MRI 3 years later. 
Exome analysis: PDE11A and ALG14
We performed a combined analysis of the nine samples (three trios, fig 2) in Ingenuity 
Variant Analysis (v5.2). From a total of 288,193 variants in 20,712 genes, a PDE11A variant 
showed up consistently in all nine subjects. In silico predictions of the pathogenicity of the 
PDE11A variant (chr2:178936272, c.893A>G, p.N298S, rs78328794) are differing: SIFT and 
AlignGVGD predict the variant: Benign (“C0” and “Tolerated”, respectively) whereas 
Mutation Taster and PolyPhen2 predict the variant: Disease causing (prob:1) and Probably 
damaging (0.998) respectively (using Alamut Visual 2.14). The variant has a frequency of 
0.11% in non-Finnish Europeans (gnomAD r2.1.1.). There are no functional studies available 
for this variant and it is not significantly associated with to testicular 20 or prostate tumours 
21. 
Another variant in the ALG14 gene also co-segregated with the AIP p.R304Q variant.  In silico 
predictions of the ALG14 variant (chr1:95538342, c.113G>T, p.S38I, rs139521179) are: 
AlignGVGD: Benign (C0), Mutation Taster: Disease causing (prob. 0.974), SIFT: Tolerated 
(0.15) and PolyPhen2: Possibly damaging (0.17). The frequency of the variant in gnomAD 
(r2.1.1) is 0.37% in non-Finnish Europeans. Individuals carrying the PDE11A or ALG14 
variants are shown in figure 2, including case 1-4.
Asymptomatic p.R304Q family members (n=10, M=7/F=3) were screened for 
the PDE11A and ALG14 variant; 3 subjects had the PDE11A variant, three the ALG14 variant 
and two subjects harbored both variants (fig 1). 
Discussion
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includes one index case with gigantism (case 1) and a second case with early-onset 
acromegaly (case 2), both of whom had a history suggestive of a pituitary apoplexy. During 
the family screening, we identified one case of a clinically non-functioning pituitary adenoma  
(case 5) that we suspected to be a phenocopy, and we identified two healthy family members 
(case 3 and 4) with acromegalic traits independent of AIP status. Based on the two patients 
with somatotropinomas, the disease penetrance was 6%. 
 Finally, based on a trio analysis, we identified two potential disease-modifying genes 
PDE11A and ALG14 by exome analysis. 
Genetic screening for AIP variants in acromegaly has so far identified 32 
patients as carriers of the p.R304Q variant 5,22,31,32,23–30, but the pathogenic role remains 
uncertain (18). Patient characteristics among the p.R304Q carriers are in some cases similar 
to overtly pathogenic AIP variants with respect to  younger age at diagnosis, large tumors 
and a family history, but there are cases with Cushing disease, which is not typical of the 
spectrum of tumor types associated with AIP mutations 25. Furthermore, two healthy 
persons with homozygous p.R304Q variant have been described in the gnomAD database 33  
and lack of loss of heterozygosity in somatotropinoma cells has been reported 34.  In line 
with this observation, most of the in vitro studies (using various techniques, such as protein 
half-life and  cell proliferation) do not support a pathogenicity of the p.R304Q variant 27,30,35–
40. However the β-galactosidase quantitative two-hybrid assay found a borderline loss of 
interaction between p.R304Q variant and PDE4A5 indicating pathogenicity 8,36. Taken 
together, the impact of the 304Q variant is still unclear, but the majority of data points 
toward a less harmful variant compared to other AIP mutations. The formal American 
College of Medical Genetics classification of this variant is ‘Variant of uncertain 
significance”41. 
We observed acromegalic features (case 3) and elevated IGF-I levels in family 
members in the absence of the AIP variant (fig 5). This could indicate the presence of 
hitherto unidentified regulatory or genetic factors predisposing to increased production and 
activity of IGF-I.  The low disease penetrance in AIP mutations and the variance in clinical 
phenotypes in a large kindred has previously been ascribed to unidentified disease-
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healthy persons with acromegalic features and five healthy relatives, we identified two 
potential disease-modifying candidate genes through exome sequencing: PDE11A and 
ALG14. 
The PDE11A is a member of the PDE family, with higher expression in pituitary 
tumours than in normal tissue, but no significant difference in PDE11A variants are reported 
between pituitary adenoma patient compared to controls 9. The PDE11A gene contains 23 
exomes and four splice variants have been identified with a dual-specificity for both cAMP 
and cGMP 42. In vitro studies of PDE11A sequence variants that were predicted in silico to 
affect function showed a decreased enzymatic activity, leading to higher levels of cAMP and 
cGMP in HEK293 cells 43. Similarly, an increased level of cAMP and a decreased PDE11A 
immunostaining were present in adrenocortical tumours tissues harboring the missense 
variants, compared with tumours with wild-type PDE11A sequence 44 . Data on adrenal, 
testicular and prostate  tumours, and even in familial breast cancer45,  suggest that defects 
in PDE11A  predispose to these tumours, but no data are available for pituitary 6,7,9. A study 
on PDE11A variants in acromegaly patients without known AIP mutations did not find an 
increase in PDE11A variants, but patients with the variants tended to exhibit a more 
aggressive phenotype 9. Moreover, in silico assessment of the PDE11A variant was classified 
as “damaging”. In the present family, all cases with acromegaly or acromegalic features 
carried the PDE11A variant but it also occurred in 50% of the tested healthy p.R304Q 
carriers (fig 1), which questions its pathogenic role. Currently it is not known whether 
genetic, epigenetic or environmental factors regulate disease penetrance, this is active field 
of research in several ‘monogenic’ diseases.  
The human ALG14 protein consists of 216 amino acids and forms a hetero-
dimeric complex together with ALG13. It is located in the endoplasmic reticulum membrane 
where it is involved in N-linked glycosylation that is essential for glycoprotein folding and 
stability 46. ALG14 mutations have been associated with severe intellectual disability and 
other neurological disorders, but so far not with pituitary disease or growth disturbances 
47,48. The ALG14 variant was in general predicted to be “tolerant” by the in silico analyses. In 
the present family, the ALG14 variant occurred in 50% of the tested healthy p.R304Q 
carriers (fig 1)
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no tumour tissue was available limited the possibilities of genetic analyses. It would be 
interesting to examine changes in the PDE11A and ALG14 gene in other cases with the 
p.R304Q AIP variant and in other familial isolated pituitary adenoma cases.  In our large 
family, we are now following 14 asymptomatic individuals carrying the p.R304Q variant 
with annual blood sampling. Therefore, the p.R304Q AIP variant remains a variant of 
unknown significance, but new cases with pituitary diseases could help to shed light on the 
role of this variant in somatotroph cell function or pituitary adenoma predisposition. 
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